ABCs Report: Streptococcus pneumoniae, 2017
This webpage is archived for historical purposes and is no longer being maintained or updated.
April 5, 2019: Content on this page kept for historical reasons.
Active Bacterial Core Surveillance (ABCs): Emerging Infections Program Network
Print-friendly version of this surveillance report Cdc-pdf[1 page]
ABCs Areas
California (3 county San Francisco Bay area); Colorado (5 county Denver area); Connecticut; Georgia (20 county Atlanta area); Maryland (6 county Baltimore area); Minnesota; New Mexico; New York (15 county Rochester and Albany areas and children <5 years in Erie county); Oregon (3 county Portland area); Tennessee (20 counties).
ABCs Population
The surveillance areas represent 34,293,143 persons.
Source: National Center for Health Statistics bridged race vintage 2017 postcensal file
ABCs Case Definition
Invasive pneumococcal disease: isolation of Streptococcus pneumoniae from normally sterile site in resident of a surveillance area in 2017.
ABCs Methodology
ABCs personnel routinely contacted all microbiology laboratories serving acute care hospitals in their area to identify cases. Standardized case report forms that include information on demographic characteristics, clinical syndrome, and outcome of illness were completed for each identified case. WGS based characterization was conducted on all pneumococcal isolates, which includes deduction of capsular serotype and MIC predictions (including PBP typing system for determining beta lactam antibiotic MICs). Conventional MIC testing is conducted on selected strains. Regular laboratory audits assessed completeness of active surveillance and detected additional cases.
Rates of invasive pneumococcal disease were calculated using population estimates for 2017 from the bridged-race vintage 2017 postcensal file. For national estimates, race and age specific rates of disease were applied from the aggregate surveillance area to the age and racial distribution of the 2017 U.S. population. Cases with missing data, excluding ethnicity, were multiply imputed using sequential regression imputation methods.¶
Reported ABCs Profiles
| Race | No. | (Rate*) |
|---|---|---|
| White | 2,234 | (8.8) |
| Black | 798 | (13.9) |
| Other | 223 | (6.8) |
* Per 100,000 population for ABCs areas
| Age (years) | Cases No. (Rate*) |
Deaths No. (Rate*) |
|---|---|---|
| < 1 | 48 (11.6) | 3 (0.72) |
| 1 | 33 (7.9) | 2 (0.48) |
| 2-4 | 66 (5.2) | 4 (0.32) |
| 5-17 | 86 (1.5) | 6 (0.11) |
| 18-34 | 203 (2.5) | 14 (0.17) |
| 35-49 | 411 (6.1) | 30 (0.44) |
| 50 64 | 1,116 (16.6) | 125 (1.86) |
| 65-74 | 618 (20.8) | 82 (2.76) |
| 75-84 | 407 (29.3) | 44 (3.16) |
| ≥ 85 | 267 (41.8) | 61 (9.56) |
| Total | 3,255 (9.5) | 371 (1.08) |
* Per 100,000 population for ABCs areas
| Syndrome | No. | (%*) |
|---|---|---|
| Meningitis | 226 | (6.9) |
| Bacteremia without focus | 533 | (16.4) |
| Pneumonia with bacteremia | 2,254 | (69.3) |
* Percent of cases
| Antibiotic Susceptibility |
S* | I† | R‡ |
|---|---|---|---|
| Penicillin+ | 96.0 | 1.7 | 2.4 |
| Cefotaxime | 97.9 | 1.8 | 0.3 |
| Erythromycin | 70.7 | 0.0 | 29.3 |
| TMP/Sulfa | 82.0 | 11.1 | 6.9 |
| Tetracycline | 88.7 | 0.0 | 11.3 |
| Levofloxacin | 99.9 | 0.0 | 0.1 |
| Vancomycin | 100 | 0.0 | 0.0 |
Based on reference lab testing of 2,897 isolates
* Susceptible; † Intermediate; ‡ Resistant based on year 2017 CLSI definitions
+ Penicillin CLSI breakpoints changed in 2009
National Estimates of Invasive Disease
Cases: 31,000 (9.5/100,000)
Deaths: 3,590 (1.10/100,000)
Healthy People 2020 Update
Objective: Decrease the incidence of invasive pneumococcal infections to 12 per 100,000 persons less than 5 years of age and to 31 per 100,000 persons aged 65 and older.
| Age (year) | 2020 Objective | 2017 Rate* |
|---|---|---|
| < 5 | 12/100,000 | 7/100,000 |
| ≥ 65 | 31/100,000 | 26/100,000 |
* Per 100,000 U.S. population < 5 years or ≥ 65 years
Citation
Centers for Disease Control and Prevention. 2017. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae, 2017.